for Sanofi Spek characterized the diabetes group as “very strong, a very, very, continued growth.” (CAC ¶ 61). In the August 1, 2013 call, Sanofi spokesperson Pascale Witz said that Lantus growth in the US was "above 20%”. (CAC ¶ 63). And, in the October 30, 2013 conference call, Viehbacher said "Diabetes continues to go along extremely strongly. You've seen the 20% growth in the third quarter. That’s the eleventh consecutive quarter of double-digit.growth.” (CAC ¶ 67). 3 . Although these excerpts from Sanofi's Form 20-Fs are not included in the text of the CAC, the Court may still rely on them in disposing of the Rule 12(b)(6) motion because the text of Sanofi's 20-Fs is incorporated in, and is integral to, the CAC. See Chambers v. Time Warner, Inc., 282 F.3d 147, 153-54 (2d Cir.2002) (<HOLDING>); see also San Lean-dro Emergency Med. Grp.
holding that an argument raised for the first time in response to defendants motion to dismiss instead of in an amended complaint was not properly raised before the district court and would not be considered on appeal holding that documents integral to the complaint are properly considered on a motion to dismiss holding that the trial court properly struck the amended complaint when the plaintiff offered no reason to refute the trial courts finding that the new allegations in the amended complaint were based on facts the plaintiff had known since the beginning of the action holding that the court may consider an article not attached to the complaint in determining whether to dismiss the complaint because the article was integral to and explicitly relied on in the complaint and because the plaintiffs did not challenge its authenticity holding that district court could properly consider the text of contracts on motion to dismiss because amended complaint was replete with references to the contracts and the content of the contracts was integral to the amended complaint